Boston Scientific (BSX) is on track to be the highest performing large cap medtech company, RBC Capital Markets said in a note emailed Friday.
The firm said it had come away more bullish on the company's 2025 setup after catching up with the company and its investors.
The firm cited the company's diversified portfolio and category leadership, as well as pipeline initiatives, as reasons to be positioned attractively in 2025.
RBC Capital also said the company's 2025 guidance was "prudent and achievable," but one that it is positioned to beat and raise from.
The firm has an outperform rating on the stock with a price target of $105.
Price: 98.76, Change: +0.59, Percent Change: +0.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。